This company listing is no longer active
SRNE.Q Stock Overview
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Sorrento Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.11 |
| 52 Week High | US$1.23 |
| 52 Week Low | US$0.021 |
| Beta | 2.1 |
| 1 Month Change | 159.95% |
| 3 Month Change | 13.27% |
| 1 Year Change | -90.59% |
| 3 Year Change | -98.50% |
| 5 Year Change | -95.49% |
| Change since IPO | -99.11% |
Recent News & Updates
Recent updates
Sorrento unit Scilex pre-emptively pays off remaining notes for $39.7M
Sep 29Sorrento Sofusa drug delivery system shows promise vs subcutaneous injection in trial
Sep 15Sorrento stock rises 13% on FDA fast track status for low back pain therapy SP-103
Aug 31Sorrento achieves positive results in pivotal trial for abivertinib in NSCLC
Aug 23Sorrento's unit Scilex inks distribution deal for pain drug ZTlido with CH Trading
Aug 17Is Sorrento Therapeutics (NASDAQ:SRNE) A Risky Investment?
Jul 22
Sorrento Therapeutics: The Enigma
Jul 15Sorrento Therapeutics subsidiary Scilex to acquire Ancora Medical
Jul 07Sorrento Therapeutics: Sales Are Up But EY Identifies Internal Control Issues
Mar 15Sorrento Therapeutics: Wide Oncology Pipeline, And Watch Out For COVID Updates
Oct 09Shareholder Returns
| SRNE.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.5% | 3.7% | 1.2% |
| 1Y | -90.6% | -1.0% | 23.7% |
Return vs Industry: SRNE.Q underperformed the US Biotechs industry which returned -8.3% over the past year.
Return vs Market: SRNE.Q underperformed the US Market which returned 21.3% over the past year.
Price Volatility
| SRNE.Q volatility | |
|---|---|
| SRNE.Q Average Weekly Movement | 106.1% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SRNE.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SRNE.Q's weekly volatility has increased from 57% to 106% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 949 | Henry Ji | www.sorrentotherapeutics.com |
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system.
Sorrento Therapeutics, Inc. Fundamentals Summary
| SRNE.Q fundamental statistics | |
|---|---|
| Market cap | US$60.35m |
| Earnings (TTM) | -US$548.00m |
| Revenue (TTM) | US$64.27m |
0.9x
P/S Ratio-0.1x
P/E RatioIs SRNE.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRNE.Q income statement (TTM) | |
|---|---|
| Revenue | US$64.27m |
| Cost of Revenue | US$221.74m |
| Gross Profit | -US$157.47m |
| Other Expenses | US$390.53m |
| Earnings | -US$548.00m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.01 |
| Gross Margin | -245.01% |
| Net Profit Margin | -852.65% |
| Debt/Equity Ratio | -71.8% |
How did SRNE.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/04 20:48 |
| End of Day Share Price | 2024/01/03 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sorrento Therapeutics, Inc. is covered by 15 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | Aegis Capital Corporation |
| James Molloy | Alliance Global Partners |
| Difei Yang | Brean Capital |